doi:10.3969/j.issn.1673-8640.2025.09.017

Abstract

CLC Number:

R446.1

Figures/Tables 8

References 24

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2]	QI J, LI M, WANG L, et al. National and subnational trends in cancer burden in China,2005-20:an analysis of national mortality surveillance data[J]. Lancet Public Health, 2023, 8(12):e943-e955.
[3]	THAI A A, SOLOMON B J, SEQUIST L V, et al. Lung cancer[J]. Lancet, 2021, 398(10299):535-554. DOI PMID
[4]	ZHANG Y, VACCARELLA S, MORGAN E, et al. Global variations in lung cancer incidence by histological subtype in 2020:a population-based study[J]. Lancet Oncol, 2023, 24(11):1206-1218.
[5]	CHAI X, ZHANG X, LI W, et al. Small cell lung cancer transformation during antitumor therapies:a systematic review[J]. Open Med(Wars), 2021, 16(1):1160-1167.
[6]	SEO H Y, KIM S C, ROH W L, et al. Culture and multiomic analysis of lung cancer patient-derived pleural effusions revealed distinct druggable molecular types[J]. Sci Rep, 2022, 12(1):6345.
[7]	LIM Z F, MA P C. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy[J]. J Hematol Oncol, 2019, 12(1):134.
[8]	SATO Y, SAITO G, FUJIMOTO D. Histologic transformation in lung cancer:when one door shuts,another opens[J]. Ther Adv Med Oncol, 2022, 14:17588359221130503.
[9]	FERONE G, SONG J Y, KRIJGSMAN O, et al. FGFR1 oncogenic activation reveals an alternative cell of origin of SCLC in Rb1/p53 mice[J]. Cell Rep, 2020, 30(11):3837-3850. DOI PMID
[10]	GIACCONE G, HE Y. Current knowledge of small cell lung cancer transformation from non-small cell lung cancer[J]. Semin Cancer Biol, 2023,94:1-10.
[11]	OFFIN M, CHAN J M, TENET M, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes[J]. J Thorac Oncol, 2019, 14(10):1784-1793.
[12]	LEE J K, LEE J, KIM S, et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas[J]. J Clin Oncol, 2017, 35(26):3065-3074.
[13]	QUINTANAL-VILLALONGA A, TANIGUCHI H, ZHAN Y A, et al. Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation[J]. Cancer Discov, 2021, 11(12):3028-3047.
[14]	中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2023版)[J]. 中华医学杂志, 2023, 103(27):2037-2074.
[15]	YATABE Y, DACIC S, BORCZUK A C, et al. Best practices recommendations for diagnostic immunohistochemistry in lung cancer[J]. J Thorac Oncol, 2019, 14(3):377-407. DOI PMID
[16]	POON I K, CHAN R C K, CHOI J S H, et al. A comparative study of diagnostic accuracy in 3 026 pleural biopsies and matched pleural effusion cytology with clinical correlation[J]. Cancer Med, 2023, 12(2):1471-1481.
[17]	张丽英, 傅冠华, 吴俊琪. 4项血清肿瘤标志物在肺癌辅助诊断和疗效评估中的价值[J]. 检验医学, 2019, 34(4):331-334. DOI
[18]	李会萍, 郑大勇, 杨帅, 等. 血清胃泌素释放肽前体在小细胞肺癌中的临床价值[J]. 检验医学, 2020, 35(4):310-313. DOI
[19]	陆沈栋, 盛泽波. 肺癌并恶性胸腔积液患者血清和胸腔积液肿瘤标志物水平变化及其对良恶性胸腔积液的鉴别诊断价值研究[J]. 实用心脑肺血管病杂志, 2018, 26(9):38-42.
[20]	MARCOUX N, GETTINGER S N, O'KANE G,et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas:clinical outcomes[J]. J Clin Oncol, 2019, 37(4):278-285.
[21]	WANG S, XIE T, HAO X, et al. Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma[J]. Thorac Cancer, 2021, 12(19):2585-2593. DOI PMID
[22]	ZUGAZAGOITIA J, PAZ-ARES L. Extensive-stage small-cell lung cancer:first-line and second-line treatment options[J]. J Clin Oncol, 2022, 40(6):671-680.
[23]	TSOU P H, CHIANG P H, LIN Z T, et al. Rapid purification of lung cancer cells in pleural effusion through spiral microfluidic channels for diagnosis improvement[J]. Lab Chip, 2020, 20(21):4007-4015.
[24]	TIAN F, LIU D, WEI N, et al. Prediction of tumor origin in cancers of unknown primary origin with cytology-based deep learning[J]. Nat Med, 2024, 30(5):1309-1319. DOI PMID

项目	CEA/（ng·mL^-1）	Pro-GRP/（pg·mL^-1）	NSE/（ng·mL^-1）
血清
2022年9月	124.07	32.76	11.88
2024年1月	125.75	567.54	54.99
2024年3月	197.77	760.85	33.78
2024年5月	77.80	1 479.68	115.30
胸腔积液
2022年9月	>1 500
2024年1月	778.56	3 538.30	>370
2024年3月	1 477.38	>5 000	>370

项目	CEA/（ng·mL^-1）	Pro-GRP/（pg·mL^-1）	NSE/（ng·mL^-1）
血清
2022年9月	124.07	32.76	11.88
2024年1月	125.75	567.54	54.99
2024年3月	197.77	760.85	33.78
2024年5月	77.80	1 479.68	115.30
胸腔积液
2022年9月	>1 500
2024年1月	778.56	3 538.30	>370
2024年3月	1 477.38	>5 000	>370

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 8

References 24

Related Articles 15

Recommended Articles

Metrics

[1]	CHU Ye, XIONG Chunxiang, HUANG Yu, ZENG Jiaxing, YI Bode, HUANG Nenggan, YANG Yifeng, YANG Feng. Role of nomogram models based on CAR and NLR in predicting 1-year mortality in elderly patients with hip fractures after surgery [J]. Laboratory Medicine, 2025, 40(9): 834-840.
[2]	XU Yingqian, WANG Jinquan, PENG Huanzi, PENG Jiaqi, HE Kun, XIE Xiaobing. Roles of serum copeptin in clinical diagnosis and prognosis evaluation of acute myocardial infarction [J]. Laboratory Medicine, 2025, 40(9): 848-855.
[3]	ZHAO Lixiao, YANG Xiaoting, LI Dan, ZHANG Nan, SU Haiyan, WANG Yan. Diagnostic roles of serum syndecan-1 and eNAMPT levels in patients with severe pneumonia complicated with sepsis [J]. Laboratory Medicine, 2025, 40(9): 856-861.
[4]	LIU Hao, FU Miao, LIU Peng, TIAN Wen, WANG Sha, YIN Xiaomei, WANG Donghai. Expressions and roles of WDR5 and miR-455-5p in cervical cancer patients [J]. Laboratory Medicine, 2025, 40(9): 867-874.
[5]	WANG Chunhong. Relationship between sd-LDL-C/HDL-C and short-term prognosis of percutaneous coronary intervention in patients with acute myocardial infarction [J]. Laboratory Medicine, 2025, 40(9): 875-880.
[6]	ZHANG Hui, YUAN Jingwen, ZHANG Chi. Adult reference ranges for platelet count and platelet-related parameters using fluorescence method in Wuhan [J]. Laboratory Medicine, 2025, 40(9): 892-896.
[7]	CHEN Wenli, JIN Cheng, ZHOU Lulu, XU Weiyi. Role of MicroR in guiding platelet count re-examination [J]. Laboratory Medicine, 2025, 40(9): 897-900.
[8]	WANG Qiuju, XIAO Huijian, WU Shuang, ZHAO Wanting, DAI Xubo, ZHUANG Yuepeng. Role of peripheral blood lymphocyte morphological classification in curative effect judgment of critical influenza [J]. Laboratory Medicine, 2025, 40(9): 901-906.
[9]	. [J]. Laboratory Medicine, 2025, 40(9): 914-917.
[10]	CHEN Fujun, CHEN Maoming. Status of clinical research on pancreatic enzyme markers [J]. Laboratory Medicine, 2025, 40(9): 918-924.
[11]	CAO Yue, SUN Qijuan, WANG Su, PAN Yiru, WANG Shiwen. Reference range of serum cystatin C in elders in Shanghai [J]. Laboratory Medicine, 2025, 40(8): 731-734.
[12]	KE Wencai, LIU Jie, LIN Yong, LU Guangjian, JIAO Luyang. Establishment and verification of nomogram diagnostic model of osteoporosis in elders based on laboratory indicators [J]. Laboratory Medicine, 2025, 40(8): 735-741.
[13]	LÜ Na, LI Fangning, BAI Qi, ZHAO Mingliang, LI Youran, CAO Yan, ZHAI Yanhong, LI Na, CAO Zheng. Correlation between short stature，tic disorders and mineral elements in whole blood [J]. Laboratory Medicine, 2025, 40(8): 742-750.
[14]	YAO Yanhong, ZHAI Chunli. Predictive role of serum amyloid A and homocysteine on pregnancy outcome in patients with gestational diabetes mellitus [J]. Laboratory Medicine, 2025, 40(8): 751-756.
[15]	SUN Yang, LI Shouxia, CAI Huixin. Correlation between serum sd-LDL-C and AIP and the severity of coronary heart disease [J]. Laboratory Medicine, 2025, 40(8): 757-762.